Economic evaluations of hepatitis B vaccination strategies - A systematic review of the literature

2.50
Hdl Handle:
http://hdl.handle.net/10029/10012
Title:
Economic evaluations of hepatitis B vaccination strategies - A systematic review of the literature
Authors:
Wit GA de; Welte R
Other Titles:
Economische evaluaties van vaccinatie tegen hepatitis B - Een systematisch literatuuronderzoek
Abstract:
National and international economic evaluations of universal vaccination against hepatitis B were systematically selected from the literature. Only the studies meeting the following criteria were selected: (a) original data reported in Dutch, English, French or German; (b) at least one universal vaccination strategy evaluated; (c) a high methodological quality shown and (d) conducting of the study in countries with a hepatitis B epidemiological pattern comparable to the Dutch situation. Sixteen relevant studies were identified out of 1060 publications registered in the databases, COCHRANE LIBRARY, CURRENT CONTENTS, DARE, HEED, INAHTA DATABASE, MEDLINE, NEED, and by applying the system of reference tracking. Despite the strict inclusion criteria, great divergence was seen among assumptions applied to a study, methodologies, outcomes and conclusions. Some studies show universal screening to be cost-saving, while others report unfavourable cost-effectiveness ratios. Studies that investigated similar vaccination strategies reach dissimilar conclusions on the most cost-effective strategy. Several parameters were found to have a usually large impact on the results and conclusions of a study. These are: a) vaccine costs, b) discount rate, c) hepatitis B incidence, d) inclusion of indirect costs and effects, e) percentage of acute infections that lead to chronic hepatitis, f) discounting effects and h) assumed lifelong costs of hepatitis B infection, including long-term consequences such as cirrhosis and liver cancer. Hence, in any further study these important variables should be subject to an extensive sensitivity analysis. Economic evaluations that are intended to assist in local policy-making should take careful account of local circumstances. The 16 selected studies have little practical relevance for Dutch policy-makers.
Affiliation:
CZO
Publisher:
Rijksinstituut voor Volksgezondheid en Milieu RIVM
Issue Date:
31-Oct-1999
URI:
http://hdl.handle.net/10029/10012
Additional Links:
http://www.rivm.nl/bibliotheek/rapporten/403505003.html
Language:
en
Series/Report no.:
RIVM Rapport 403505003
Appears in Collections:
RIVM reports - old archive

Full metadata record

DC FieldValue Language
dc.contributor.authorWit GA deen_US
dc.contributor.authorWelte Ren_US
dc.date.accessioned2007-03-09T15:58:31Z-
dc.date.available2007-03-09T15:58:31Z-
dc.date.issued1999-11-00en_US
dc.identifier403505003en_US
dc.identifier.urihttp://hdl.handle.net/10029/10012-
dc.description.abstractNational and international economic evaluations of universal vaccination against hepatitis B were systematically selected from the literature. Only the studies meeting the following criteria were selected: (a) original data reported in Dutch, English, French or German; (b) at least one universal vaccination strategy evaluated; (c) a high methodological quality shown and (d) conducting of the study in countries with a hepatitis B epidemiological pattern comparable to the Dutch situation. Sixteen relevant studies were identified out of 1060 publications registered in the databases, COCHRANE LIBRARY, CURRENT CONTENTS, DARE, HEED, INAHTA DATABASE, MEDLINE, NEED, and by applying the system of reference tracking. Despite the strict inclusion criteria, great divergence was seen among assumptions applied to a study, methodologies, outcomes and conclusions. Some studies show universal screening to be cost-saving, while others report unfavourable cost-effectiveness ratios. Studies that investigated similar vaccination strategies reach dissimilar conclusions on the most cost-effective strategy. Several parameters were found to have a usually large impact on the results and conclusions of a study. These are: a) vaccine costs, b) discount rate, c) hepatitis B incidence, d) inclusion of indirect costs and effects, e) percentage of acute infections that lead to chronic hepatitis, f) discounting effects and h) assumed lifelong costs of hepatitis B infection, including long-term consequences such as cirrhosis and liver cancer. Hence, in any further study these important variables should be subject to an extensive sensitivity analysis. Economic evaluations that are intended to assist in local policy-making should take careful account of local circumstances. The 16 selected studies have little practical relevance for Dutch policy-makers.en
dc.format.extent429000 bytesen_US
dc.format.extent438439 bytes-
dc.format.mimetypeapplication/pdf-
dc.language.isoenen_US
dc.publisherRijksinstituut voor Volksgezondheid en Milieu RIVMen_US
dc.relation.ispartofseriesRIVM Rapport 403505003en_US
dc.relation.urlhttp://www.rivm.nl/bibliotheek/rapporten/403505003.htmlen_US
dc.subject.otherpreventionen
dc.subject.othervaccinationen
dc.subject.othereconomic evaluationen
dc.subject.otherliteratureen
dc.subject.otherreviewen
dc.subject.othercost-effectiveness-analysisen
dc.subject.otherhepatitis bnl
dc.subject.otherpreventienl
dc.subject.othervaccinatienl
dc.subject.othereconomische evaluatienl
dc.subject.otherliteratuuronderzoeknl
dc.subject.otherkosten-effectiviteits-analysenl
dc.titleEconomic evaluations of hepatitis B vaccination strategies - A systematic review of the literatureen_US
dc.title.alternativeEconomische evaluaties van vaccinatie tegen hepatitis B - Een systematisch literatuuronderzoeken_US
dc.contributor.departmentCZOen_US
All Items in WARP are protected by copyright, with all rights reserved, unless otherwise indicated.